Person:
DURDU, BÜLENT

Loading...
Profile Picture
Status
Organizational Units
Organizational Unit
Job Title
First Name
BÜLENT
Last Name
DURDU
Name
Email Address
Birth Date

Search Results

Now showing 1 - 10 of 28
  • PublicationOpen Access
    Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19
    (2020-09-25T00:00:00Z) Koç, Mm; Kalkan, Yazıcı; Çetin, Nesibe Selma; Doymaz, Mz; Sümbül, B; Durdu, B; YAZICI, MERVE; MERİÇ KOÇ, MELİHA; ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; OKAY, GÜLAY; DURDU, BÜLENT; SÜMBÜL, BİLGE; DOYMAZ, MEHMET ZIYA
    The recent pandemic of COVID-19 has caused a tremendous alarm around the world. Details of the infection process in the host have significant bearings on both recovery from the disease and on the correlates of the protection from the future exposures. One of these factors is the presence and titers of neutralizing Abs (NAbs) in infected people. In the current study, we set out to investigate NAbs in the recovered subjects discharged from the hospital in full health. Serum samples from a total of 49 documented consecutive COVID-19 subjects were included in the study. All the subjects were adults, and serum samples collected during the discharge were tested in viral neutralization, enzyme immunoassay (EIA), and Western immunoblot tests against viral Ags. Even though a majority of the recovered subjects had raised significant NAb titers, there is a substantial number of recovered patients (10 out of 49) with no or low titers of NAbs against the virus. In these cohorts as well as in patients with high NAb titers, viral Ag binding Abs were detectable in EIA tests. Both NAb titers and EIA detectable Abs are increased in patients experiencing a severe form of the disease, and in older patients the Ab titers were heightened. The main conclusion is that the recovery from SARS-CoV-2 infection is not solely dependent on high NAb titers in affected subjects, and this recovery process is probably produced by a complex interplay between many factors, including immune response, age of the subjects, and viral pathology.
  • PublicationMetadata only
    Examination of antimicrobial effect of fluoxetine in experimental sepsis model: An in vivo study
    (2022-10-01T00:00:00Z) Cakir, Ahsen; Bozali, Kubra; Celikten, Mert; Guler, Eray Metin; Sahan, Ebru; DURDU, BÜLENT; SÜMBÜL, BİLGE; KOÇYİĞİT, ABDÜRRAHİM; ŞAHAN, EBRU; DURDU, BÜLENT; SÜMBÜL, BİLGE; KOÇYİĞİT, ABDÜRRAHİM
    Since most infectious diseases can develop into sepsis, it is still a major medical problem. Some in-vivo studies showed promising properties of fluoxetine in the treatment of infections. This study aims the antimicrobial effect of fluoxetine on the inflammatory process used in the treatment of sepsis-modeled rats. Besides, to investigate the efficacy of fluoxetine on modifying the antibiotic effect of imipenem in the inflammatory response. An experimental sepsis model was divided into negative control, positive control, fluoxetine 5 mg/kg, imipenem 60 mg/kg, and combined (fluoxetine; imipenem). Procalcitonin (PCT), high-sensitivity C-reactive protein (hs-CRP), lactate, myeloperoxidase activity (MPO), the inflammation markers interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), tumor necrosis factor-alfa (TNF-alpha), and monocyte chemoattractant protein-1 (MCP-1) levels were measured by enzyme-linked immunosorbent assay method. Oxidative stress markers, total oxidant status (TOS), total antioxidant status (TAS), total thiol (TT), and native thiol (NT) were measured using photometric methods. Oxidative stress index (OSI) was calculated according to TAS and TOS levels. The statistical analysis was performed by Statistical Package for Social Sciences version 22.0. After treatment with fluoxetine, imipenem, and combined groups, IL-1 beta, IL-6, TNF-alpha, MPO activity, MCP-1, hs-CRP, PCT, lactate, and the oxidative stress markers OSI, and disulfide levels were decreased (p < 0.05). The TT, NT, and TAS levels significantly statistically increased (p < 0.05). This research demonstrates that fluoxetine has effects as anti-inflammatory and antioxidant, and the combined treatment with antibioticum imipenem indicates positive synergistic effects in the experimental sepsis model.
  • PublicationMetadata only
    Utility of Rapid Antibody Test for Screening COVID-19 Among Healthcare Professionals
    (2020-10-01T00:00:00Z) Okay, Gulay; Kacmaz, Asiye Bahar; Sumbul, BİLGE; Bolukcu, Sibel; Akkoyunlu, Yasemin; Meric Koc, Meliha; SÜMBÜL, BİLGE; OKAY, GÜLAY; DURDU, BÜLENT; AKKOYUNLU, YASEMİN
    Objective: This study aims to assess the effectivity of a rapid antibody test on detecting the occupational exposure in healthcare professionals who have been working in a pandemic hospital since the initial cases were seen in our country.
  • PublicationOpen Access
    COVİD-19 infection in a membranous nephropathy patient treated with rituximab.
    (2020-09-04T00:00:00Z) Elcioglu, Omer Celal; Artan, Ayse Serra; Mirioglu, Safak; Gursu, Meltem; Durdu, Bulent; Koc, Meliha Meric; Okyaltirik, Fatmanur; Gultekin, Mehmet Ali; Kazancioglu, Rümeyza; ELÇİOĞLU, ÖMER CELAL; MİRİOĞLU, ŞAFAK; GÜRSU, MELTEM; DURDU, BÜLENT; MERİÇ KOÇ, MELİHA; OKYALTIRIK, FATMANUR; GÜLTEKİN, MEHMET ALİ; KAZANCIOĞLU, RÜMEYZA
    While COVID-19 pandemic continues to afect our country and most countries in the world, we have to make some changes both in our social life and our approach to healthcare. We have to struggle with the pandemic on one hand and also try to follow up and treat our patients with chronic diseases in the most appropriate way. In this period, one of our group of patients who are challenging us for follow-up and treatment are those who should start or continue to use immunosuppressive therapy. In order to contribute to the accumulation of knowledge in this area, we wanted to report a patient who was followed up with the diagnosis of COVID-19 and had been administered rituximab very recently due to a nephrotic syndrome caused by membranous nephropathy.
  • PublicationMetadata only
    Investigation of drug-related problems in hospitalized patients with respiratory diseases: a randomized controlled trial
    (2022-11-25) Bektay M. Y.; Sancar M.; Okyaltırık F.; Durdu B.; İzzettin F. V.; BEKTAY, MUHAMMED YUNUS; OKYALTIRIK, FATMANUR; DURDU, BÜLENT; İZZETTİN, FIKRET VEHBI
  • PublicationOpen Access
    A case of meralgia paresthetica caused by prone positioning in a COVID-19 patient with acute respiratory distress syndrome
    (2022-01-01T00:00:00Z) Karaaslan, Tahsin; Avarisli, Aysenur; DURDU, BÜLENT; DAŞKAYA, HAYRETTİN; DURDU, BÜLENT; DAŞKAYA, HAYRETTİN
    COVID-19 critically ill patients usually require prone positioning for the treatment of respiratory failure caused by Acute Respiratory Distress Syndrome (ARDS). Prone position provides a better ventilation-perfusion compatibility, resulting in a significant improvement in oxygenation and a decrease in mortality, but prolonged prone positioning may cause Meralgia Paresthetica (MP), one of the most common mononeuropathies of the lower limb. The early diagnosis of MP is crucial to avoid a permanent damage with pain and disability, and to start immediately the correct treatment. In this article, we report a rare case of MP in a critically ill COVID-19 patient with ARDS, with the main aim to create awareness for MP among the medical team working.
  • PublicationMetadata only
    Covid-19 pandemisinde hastalık hastane yönetimi
    (2021-01-01T00:00:00Z) DURDU, BÜLENT; AKKOYUNLU, YASEMİN; DURDU, BÜLENT; AKKOYUNLU, YASEMİN
  • PublicationMetadata only
    Türkiye Klinikleri Enfeksiyon Hastalıkları - Özel Konular Fırsatçı Mantar Enfeksiyonları
    (2020-09-01T00:00:00Z) Durdu, Bülent; Meriç Koç, Meliha; DURDU, BÜLENT; MERİÇ KOÇ, MELİHA
  • PublicationMetadata only
    İmmünsupresif Hastada İntramuskuler Apselerle Seyreden Salmonella Enterica Bakteriyemisi
    (2021-05-20T00:00:00Z) Özmen, Mehmet Emin; Okay, Gülay; Yüce, Nurgül; Durdu, Bülent; Aslan, Turan; Meriç Koç, Meliha; ÖZMEN, MEHMET EMİN; OKAY, GÜLAY; ANDIÇ, NURGÜL; DURDU, BÜLENT; ASLAN, TURAN; MERİÇ KOÇ, MELİHA
  • PublicationMetadata only
    Investigation of pharmaceutical care need of COVID-19 patients in hospital settings
    (2021-12-01T00:00:00Z) BEKTAY, MUHAMMED YUNUS; İZZETTİN, Fikret Vehbi; DURDU, BÜLENT; OKYALTIRIK, Fatmanur; SANCAR, MESUT; BEKTAY, MUHAMMED YUNUS; OKYALTIRIK, FATMANUR; DURDU, BÜLENT; İZZETTİN, FIKRET VEHBI